Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Hims & Hers’

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers stock rallies after announcing a partnership with Novo Nordisk. Analyst says there’s potential for further upside in HIMS shares.

Barchart

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Missed the Hims & Hers Rally? Clover Health Could Be Next

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

MarketBeat

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

Barchart

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

MarketBeat

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

MarketBeat

Ozempic, Wegovy maker claps back at Hims & Hers Super Bowl ad: ‘Check before you inject’

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Fortune

Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

LiveScience

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

Fortune

Super Bowl commercials 2025: Post Malone Oreos, Chris Hemsworth and Chris Pratt team up, and more ads to watch right now

Plenty of brands are already sharing or teasing their Super Bowl 2025 ads. Here are all the ads we've seen during today's big game.

Tom’s Guide

Hims & Hers Health: A Stock to Trade or Own?

HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.

MarketBeat

Erectile Dysfunction Treatment Provider Donates $1 Million to Trump Inauguration

Hims & Hers is the latest US corporation to donate $1 million to President-elect Donald Trump's ever-growing inauguration fund.

Latin Times

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

Barchart

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Fortune

Hims & Hers’ surprise 85% Wegovy discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says

The compounded weight loss drug starts at $199 per month.

Barchart

After Doubling in the Past 6 Months, Will Hims & Hers Health Stock Continue Higher?

Telehealth company Hims & Hers is trading near record highs after issuing strong guidance for the full year ahead. With the stock up nearly 145% in the last six months, how much more upside is left for HIMS?

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Subscription-based care moves beyond peddling birth control and helping with hair loss

Online, direct-to-consumer health care has grown well beyond its roots mostly treating hair loss and acne or selling birth control pills

Marie Claire

This is exactly how often you should be having sex to boost health and happiness, according to research

Your need-to-knows.

Tribune News Service

Digital mental health companies draw scrutiny and growing concerns

When Pat Paulson’s son told her he was feeling anxious and depressed at college, Paulson went through her Blue Cross Blue Shield provider directory and started calling mental health therapists. No providers in the Wisconsin city where her son’s university is located had openings. So she bought a monthly subscription…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

224 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.